RECCE PHARMACEUTICALS LTD — Capital/Financing Update 2024

Jul 8, 2024

ASX Announcement

9 July 2024

==> picture [416 x 93] intentionally omitted <==

Cleansing notice under section 708A(5)(e) of the Corporations Act

This notice is being given by Recce Pharmaceuticals Ltd ( ASX:RCE ) ( Recce or Company ) under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ).

The Company today issued 17,777,788 fully paid ordinary shares ( New Shares ) at an issue price of $0.45 per New Share to institutional and sophisticated investors under the placement announced on 2 July 2024.

For the purposes of section 708A(6) of the Corporations Act, the Company advises that:

• (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

• (b) this notice is being given under section 708A(5)(e) of the Corporations Act;

• (c) as at the date of this notice, the Company has complied with:

  • i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

  • ii. sections 674 and 674A of the Corporations Act; and

• (d) as at the date of this notice, there is no information that is ‘excluded information’ of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act, which is required to be disclosed by the Company.

In accordance with paragraph 7(f) of ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 , this notice also serves as a cleansing notice for the securities purchase plan of Recce.

This announcement has been approved for release by the Board.

For more information, please contact:

Maggie Niewidok Company Secretary

==> picture [467 x 44] intentionally omitted <==